1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,097 | 0,117 | 09:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 06.11. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 30.10. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 15.10. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.10. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 27.09. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT COMPLETION OF JOINT-STOCK CONVERSION OF VIVA SHANGHAI AND CHANGE OF ROLES OF CO-CHIEF FINANCIAL OFFICER | - | HKEx | ||
| 26.09. | VIVA BIOTECH (01873): INTERIM REPORT 2024 | - | HKEx | ||
| 25.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 13.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 13.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS (REVISED) | 1 | HKEx | ||
| 05.09. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08. | Viva Biotech Holdings: Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | 69 | PR Newswire | Results Highlights for Interim Results ended 30 June 2024
Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS... ► Artikel lesen | |
| 29.08. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE | - | HKEx | ||
| 29.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 28.08. | VIVA BIOTECH (01873): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDER AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 28.08. | VIVA BIOTECH (01873): NOTIFICATION LETTER TO REGISTERED SHAREHOLDER - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 19.08. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.07. | VIVA BIOTECH (01873): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 03.07. | VIVA BIOTECH (01873): CLARIFICATION ANNOUNCEMENT | - | HKEx | ||
| 26.06. | VIVA BIOTECH (01873): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 2 | HKEx |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,010 | -0,89 % | Deutsche Telekom, GFT Technologies, TeamViewer, TUI, RWE, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| NOVONESIS | 56,60 | -0,74 % | Novonesis (Novozymes A/S): Major shareholder announcement | ||
| GENMAB | 196,50 | +0,15 % | Jefferies cuts Genmab's PT by 23% on uncertain development pipeline | ||
| ARBUTUS BIOPHARMA | 3,310 | +1,72 % | Arbutus Biopharma Corporation: Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon | 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved... ► Artikel lesen | |
| BEIGENE LTD ADR | 186,00 | +2,20 % | With patent settlement, BeiGene defends blockbuster Brukinsa from MSN's generic threat until 2037 | ||
| MOLECULIN BIOTECH | 2,360 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia ... | Company on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025
Trial designed for possible... ► Artikel lesen | |
| VERICEL | 55,00 | -1,79 % | Vericel Corporation: Vericel Reports Third Quarter 2024 Financial Results | Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third... ► Artikel lesen | |
| SINO BIOPHARM | 0,400 | +0,05 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION ... | ||
| SENSEI BIOTHERAPEUTICS | 0,568 | -1,39 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,450 | +0,45 % | BioXcel Therapeutics Aktie: Unveränderte Prognosen erwartet | Die BioXcel Therapeutics Aktie verzeichnete am 23. November 2024 einen positiven Handelstag mit einem Anstieg von 4,08 Prozent auf 0,51 EUR. Die Biotech-Firma, die sich auf neurowissenschaftliche und... ► Artikel lesen | |
| ZAI LAB LTD ADR | 26,000 | -2,99 % | As other Big Pharmas face local headwinds, Pfizer doubles down on China commitment with Zai Lab antimicrobial marketing pact | ||
| MUSTGROW BIOLOGICS | 1,220 | -1,61 % | MustGrow Biologics Corp.: MustGrow Provides 2024 Pipeline Update | MustGrow transitions from R&D to commercialization.TerraSanteTM biofertility product manufacturing and sales has commenced, with potential initial sales ramp-up in 2025 and 2026.Commercialization of... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,250 | +2,46 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE AND PHARMALINK ENTER INTO STRATEGIC PARTNERSHIP FOR SUGEMALIMAB IN MIDDLE EAST AND NORTH AFRICA ... | ||
| REGENXBIO | 9,200 | +0,55 % | Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy | ||
| AKEBIA | 1,834 | +0,27 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025
Over 300,000 patients, representing approximately 60% of dialysis patient... ► Artikel lesen |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,003 (+2,51 %) liegt der Kurs bei 0,102 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.
